Mesoblast Limited

(MESO) Trade

By |

Profile

Mesoblast is developing adult stem cell therapies based on its proprietary mesenchymal precursor stem cell and culture-expanded mesenchymal stem cell technology platforms. It has nine clinical trial programs across four major areas (cardiovascular, spine disease, immunologic/inflammatory, and cancer) targeting chronic diseases affecting large populations.

Contact Information

Website: www.mesoblast.com
Email: michael.schuster@mesoblast.com
Main Phone: +61 396396036
Address: Level 38, 55 Collins Street
State: VIC
City / Town: Melbourne
Country: AUS
Postal Code: 3000

Issuer Information

Exchange: NGS
CEO: Silviu Itescu
Employees: 81
NAICS: 541711
$ 4.13 $ -0.2741 (-6.23%)
Last Price 4.13 Change $ -0.2741 Change % -6.23 Tick N/A
Bid N/A Bid Size 0.00 Ask 5.94 Ask Size 200.00
Open 4.38 High 4.38 Low 4.08 Prev Close 4.40
Last Trade Volume 45,084 52 Wk Hi 8.78 52 Wk Low 4.00
Market Cap 398.5 mi Ex-Div Date N/A Div Rate N/A Yield N/A
Shares 96,580,330.00 EPS (TTM) -0.50 PE Ratio N/A Exchange NGS
  Current 1 Week Ago 2 Weeks Ago 3 Weeks Ago
High Target Price Estimate 23 23 23 23
Low Target Price Estimate 5.5 5.5 5.5 5.5
Mean Target Price Estimate 14.79 14.35 14.35 14.79
Standard Deviation 5.71 6.27 6.27 5.71
Date of Most Recent Estimate 06/07/18 05/31/18 04/18/18 06/07/18
  Current 1 Month Ago 2 Months Ago 3 Months Ago
Strong Buy 5 4 4 4
Moderate Buy 0 0 0 0
Hold 1 1 1 1
Moderate Sell 0 0 0 0
Strong Sell 0 0 0 0
Mean Rec. 1.33 1.4 1.4 1.4